Krilov L R, Anderson L J, Marcoux L, Bonagura V R, Wedgwood J F
Division of Infectious Diseases, Schneider Children's Hospital, Long Island Jewish Medical Center, New Hyde Park, NY 11042.
J Infect Dis. 1989 Nov;160(5):777-82. doi: 10.1093/infdis/160.5.777.
Monoclonal antibodies (MAbs) specific for two surface glycoproteins of respiratory syncytial virus (RSV) were found to enhance RSV infection in two macrophagelike cell lines (P388D1 and THP-1). MAbs to an irrelevant antigen (pneumococcal polysaccharide) and to the nucleocapsid of RSV did not enhance infection. Blocking either the Fc segment of the monoclonal antibody of the Fc receptor on the cells diminished the enhancement, suggesting that this phenomenon involves attachment of the monoclonal antibody to the virus followed by attachment of the Fc of this complex to the Fc receptor on the cells. These data indicate that antibody-mediated enhancement of RSV infection can occur in vitro in macrophages. This enhancement may contribute to the pathogenesis of RSV bronchiolitis and the more severe RSV disease seen in recipients of formalin-inactivated RSV vaccine.
发现针对呼吸道合胞病毒(RSV)两种表面糖蛋白的单克隆抗体(MAb)可增强两种巨噬细胞样细胞系(P388D1和THP-1)中的RSV感染。针对无关抗原(肺炎球菌多糖)和RSV核衣壳的单克隆抗体不会增强感染。阻断细胞上Fc受体的单克隆抗体的Fc段可减弱这种增强作用,这表明该现象涉及单克隆抗体与病毒的结合,随后该复合物的Fc与细胞上的Fc受体结合。这些数据表明,抗体介导的RSV感染增强可在体外巨噬细胞中发生。这种增强可能有助于RSV细支气管炎的发病机制以及在接受甲醛灭活RSV疫苗的人群中出现的更严重的RSV疾病。